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Appropriate health and nutrition interventions to prevent long-term adverse effects in chil-
dren are necessary before two years of age. One such intervention may include population-
based deworming, recommended as of 12 months of age by the World Health Organization
in soil-transmitted helminth (STH)-endemic areas; however, the benefit of deworming has
been understudied in early preschool-age children.
Methodology/Principal Findings
A randomized, double-blind, placebo-controlled trial was conducted to determine the effect of
deworming (500mg single-dose crushed mebendazole tablet) on growth in one-year-old chil-
dren in Iquitos, Peru. Children were enrolled during their routine 12-month growth and devel-
opment clinic visit and followed up at their 18 and 24-month visits. Children were randomly
allocated to: Group 1: deworming at 12 months and placebo at 18months; Group 2: placebo
at 12 months and deworming at 18months; Group 3: deworming at both 12 and 18months;
or Group 4: placebo at both 12 and 18months (i.e. control group). The primary outcome was
weight gain at the 24-month visit. An intention-to-treat approach was used. A total of 1760
children were enrolled between September 2011 and June 2012. Follow-up of 1563 children
(88.8%) was completed by July 2013. STH infection was of low prevalence and predomi-
nantly light intensity in the study population. All groups gained between 1.93 and 2.05 kg on
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average over 12 months; the average difference in weight gain (kg) compared to placebo
was: 0.05 (95%CI: -0.05, 0.17) in Group 1; -0.07 (95%CI: -0.17, 0.04) in Group 2; and 0.04
(95%CI: -0.06, 0.14) in Group 3. There was no statistically significant difference in weight gain
in any of the deworming intervention groups compared to the control group.
Conclusions
Overall, with one year of follow-up, no effect of deworming on growth could be detected in
this population of preschool-age children. Low baseline STH prevalence and intensity and/
or access to deworming drugs outside of the trial may have diluted the potential effect of the
intervention. Additional research is required to overcome these challenges and to contribute




TheWorld Health Organization recommends starting population-based deworming inter-
ventions as of 12 months of age where intestinal worm infection is common; however, lit-
tle is known about the benefits in early preschool-age children. We conducted a clinical
trial to determine the effect of deworming on growth in one-year-old children in Peru.
Participating children were randomly assigned to: 1) deworming at 12 months of age; 2)
deworming at 18 months of age; 3) deworming at 12 and 18 months of age; or 4) no
deworming (i.e. control group). A total of 1760 children were enrolled between September
2011 and June 2012, and followed up for one year. Overall, with one year of follow-up, no
effect of deworming on growth could be detected in this population of preschool-age chil-
dren. The potential benefit of the intervention may have been affected by low baseline
infection prevalence and/or low compliance to the randomly assigned intervention. Addi-
tional research is required to overcome these challenges and to contribute to strengthening
the evidence base on deworming.
Introduction
The soil-transmitted helminth (STH) disease cluster includes ascariasis, trichuriasis and hook-
worm disease. It is considered to be one of the most common Neglected Tropical Diseases
(NTD), affecting an estimated 1.45 billion people worldwide [1]. STHs are transmitted in con-
taminated food, water and the environment in areas of poverty in low- and middle-income
countries. These intestinal parasites have a direct and indirect adverse impact on nutritional
status by disrupting normal nutrient intake, excretion and utilization in their hosts and by
causing blood loss and loss of appetite [2,3].
WHO recommends large-scale preventive chemotherapy programs, using anthelminthic
treatment (i.e. deworming), for the high-risk groups of women of reproductive age, especially
pregnant women, school-age children (i.e. 5 to 14 years of age), and preschool-age children (i.e.
1 to 4 years of age) in STH-endemic areas [4,5]. Adverse effects from deworming are infre-
quent, and when reported, are mild and transitory, including gastrointestinal upset and
An RCT of Deworming in One-Year-Old Children in Peru
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004020 October 1, 2015 2 / 20
Foreign Study Supplement; Planning and
Dissemination Grant), the Research Institute of the
McGill University Health Centre (http://muhc.ca/
research) and the Fonds de Recherche du Québec–
Santé (www.frsq.gouv.qc.ca). The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
diarrhea [6]. Deworming interventions are often school-based in order to reach school-age
children. In preschool-age children, deworming is often piggybacked onto vaccination or sup-
plementation programs, child health days, or programs for the elimination of lymphatic filaria-
sis [7]. However, preschool-age children lag behind their school-age counterparts as scaling-up
of school-based programs continues while that of preschool programs remains a challenge [7].
The global proportion of at-risk preschool-age children receiving deworming in 2012 was esti-
mated to be on the order of 25% [7]. This coverage has decreased since previous reports [8].
Prior to 2002, children under two years of age had been excluded from deworming interven-
tions as the burden of STH infection was perceived to be low in this age group and the safety
profile of available anthelminthics was not well established. In 2002, WHO convened an infor-
mal consultation of experts, and subsequently recommended the inclusion of children between
12 and 24 months of age in deworming activities using single-dose albendazole (in a reduced
dose of 200 mg) or mebendazole (in the usual dose of 500 mg) [9]. These recommendations
were based on animal studies, toxicity data and other safety data [10]. Despite the WHO rec-
ommendations and increasing evidence of the occurrence of STH infection in early preschool-
age children [10–15], many countries still exclude children under 24 months of age from their
national deworming programs. Providing evidence on the potential benefits of deworming in
the younger age group between one and two years of age is essential. A study reviewing data
from 54 countries confirmed that preventive interventions must occur during the first two
years of life to prevent growth deficits, such as stunting and underweight [16]. Interventions at
this time are essential to prevent both short- and longer-term adverse health effects [17]. The
evidence-base on including deworming as one of the essential early childhood interventions in
this critical window is, however, limited. Randomized controlled trials conducted exclusively in
school-age children or in both preschool-age and school-age children have provided mixed evi-
dence on deworming benefits on growth and development [6,18,19]. Few studies have focused
exclusively on the preschool-age population [12,20–22]. There is some evidence that adverse
consequences of even low prevalence and intensity STH infection may be more pronounced in
children during this critical time period [11].
Considering the unique nutritional demands and growth patterns of younger children,
aggregated results from older children do not provide a clear indication of the potential benefit
of deworming on growth and nutrition in younger age groups. To fill this research gap, we
therefore conducted a randomized controlled trial on the effect, and optimal timing and fre-
quency, of a deworming intervention incorporated into routine child health services at one
year of age. Our objective was to determine whether deworming would improve growth by two
years of age.
Methods
Ethics approval and trial monitoring
This study received ethics approval in Peru from the Comité Institucional de Ética of the Uni-
versidad Peruana Cayetano Heredia and the Instituto Nacional de Salud, in Lima, and the local
Ministry of Health office (Dirección Regional de Salud (DIRESA) Loreto) in Iquitos (S1 Text).
Ethics approval was obtained in Canada from the Research Ethics Board of the Research Insti-
tute of the McGill University Health Centre in Montréal, Québec (S1 Text). An independent
Data Safety and Monitoring Committee (DSMC) was established with three members, from
Canada, the U.S., and Peru, to review all adverse events and approve continuation of the trial at
three time points. At baseline, eligibility was assessed, and an informed consent form was
signed by both parents or guardians of the child. In the case of a single parent (e.g. due to
death, separation or divorce), only one signature was required. The trial was registered with
An RCT of Deworming in One-Year-Old Children in Peru
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004020 October 1, 2015 3 / 20
ClinicalTrials.gov (NCT01314937). The CONSORT checklist is described in S1 Checklist and
the trial protocol is described in S2 Text.
Study design and enrollment procedures
We conducted a randomized, double-blind, parallel, placebo-controlled trial of a deworming
intervention incorporated into routine growth and development (‘Crecimiento y Desarrollo”
or CRED) visits in Iquitos, an STH-endemic area of the Peruvian Amazon. Details on baseline
enrolment methodology and the study population have been described elsewhere [14]. Briefly,
children were enrolled into the trial in their homes or participating health centres. Inclusion
criteria were: 1) children attending any one of the 12 participating health centres for their
12-month CRED visit; and 2) children living in Belén, Iquitos, Punchana or San Juan districts.
Exclusion criteria were: 1) children attending the health centre for suspected STH infection; 2)
children who had received deworming treatment in the six months prior to the trial; 3) chil-
dren whose families planned to move outside of the study area within the next 12 months; 4)
children under 12 months of age or 14 months of age or older; and 5) children with any serious
congenital or chronic medical condition. Any child who was excluded for medical reasons, and
who was not already receiving regular health care, was referred to the health centre for follow-
up by appropriate health personnel.
A baseline socio-demographic and epidemiological questionnaire (including family and
child health and nutrition information) was administered in the home or health centre to the
primary caregiver of the child. Baseline outcome measurements, including weight, length and
the provision of a stool specimen, were ascertained in a subsequent visit in the health centre.
All procedures were performed by dedicated, trained research assistants.
Intervention groups
Following confirmation of eligibility, informed consent and all baseline outcome assessments
in the health centres, children were randomized into one of four intervention groups:
Group 1 (MBD/PBO): Usual care and deworming at the 12-month CRED visit and usual care
and placebo at the 18-month CRED visit.
Group 2 (PBO/MBD): Usual care and placebo at the 12-month CRED visit and usual care and
deworming at the 18-month CRED visit.
Group 3 (MBD/MBD): Usual care and deworming at both the 12 and 18-month CRED visits.
Group 4 (PBO/PBO): Usual care and placebo at both the 12 and 18-month CRED visits (i.e.
control group).
Deworming consisted of a single-dose mebendazole tablet (500 mg) (manufactured by Jans-
sen Pharmaceuticals Inc.; donated by INMED Peru). The placebo was identical to the deworm-
ing tablet in terms of size, colour and markings (manufactured and purchased from
Laboratorios Hersil, Peru). Tablets were crushed and mixed with juice for ease of administra-
tion and safety [23]. The crushed tablet was administered by research assistants at the end of
each visit after all outcome assessments had been completed. All children received deworming
at the 24-month visit according to Peruvian Ministry of Health guidelines [24]. Children
received usual care interventions and services from health centre personnel [24]. This included
the administration of measles, mumps and rubella (MMR) vaccination at the 12-month visit,
and diphtheria, pertussis and tetanus (DPT) vaccine booster at the 18-month visit.
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Sample size
Sample size calculations were based on detecting the smallest meaningful difference among
intervention groups in mean weight gain over 12 months, and took into account potential
effect dilution from treating infected and non-infected children. From previous research in the
study area, STH prevalence was expected to be 25% at 12 months of age [13]. To estimate
expected growth, longitudinal growth data was collected from health centre registries in the
study area in 2011. Mean weight gain ± standard deviation between 12 and 24 months in 100
untreated children was calculated to be 2.0 kg ± 0.8 kg. The sample size was calculated a priori
such that comparisons could be made between all four groups to look at the overall effect of
deworming, as well as the effect of timing and frequency of deworming.
In order to have 80% power to detect a minimum difference of 0.20 kg in mean weight gain
among intervention groups, assuming a common standard deviation of 0.8 and a significance
level of 0.05, and using a one-way ANOVA which accounts for pair-wise multiple comparisons
between all groups (i.e. 6 comparisons) using the Tukey correction, the estimated sample size
per group was 366 children. The required sample size was increased to 440 children per group
(1760 in total), to take into account potential loss-to-follow-up of 20% after 12 months (based
on attrition rates from previous studies in the area by the research team [25,26]) (MC4G Soft-
ware©, GP Brooks, Ohio University, 2008).
Randomization and masking
Computer-generated randomly ordered blocks of eight and twelve were used to randomly
assign children to each intervention group in a 1:1:1:1 allocation ratio. Blocking ensured that
the number of children assigned to each group would be balanced and reduced the potential
for bias and confounding [27]. The random allocation sequence was generated by a biostatisti-
cian who was not otherwise involved in the trial. Research personnel not directly involved in
the trial prepared small envelopes containing the randomly assigned intervention for each visit.
These were numbered from 1 to 1760, with each number corresponding to one of the four
intervention groups. Envelopes were stored in a temperature-regulated pharmacy at the
research facility, and distributed by the Project Director (SAJ) or the local Study Coordinator
(LP) in sequential order to research assistants until the sample size was achieved. Appropriate
allocation concealment and randomly ordered block sizes ensured that the randomization
sequence would not be predictable [27]. All health centre and research personnel, and parents
of participants were blinded to intervention status.
Follow-up visits
Children were followed-up at their 18 and 24-month visit in the health centre, at which time all
outcome ascertainments were repeated. At the 18-month visit the second randomly assigned
intervention was administered. Each visit was scheduled six months after the previous visit. In
the case that a participant did not attend their 18-month visit, children remained eligible for
the 24-month visit, which was scheduled 12 months after initial enrolment. If participants were
not located prior to the day of their anticipated follow-up visit, or a scheduled date was missed,
a minimum of four additional attempts were made to locate them. The original end dates of
the 18-month follow-up and 24-month follow-up (i.e. trial completion) were each extended by
one month (i.e. seven months and 13 months after the end of enrolment, respectively) to maxi-
mize follow-up rates. A monetary reimbursement was provided to cover travel costs for each
visit.
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Outcome measurements
The pre-specified primary outcome measure was weight gain between the 12 and 24-month
visit. Pre-specified secondary outcome measures were weight-for-age z-score, length gain,
length-for-age z-score, change in STH infection prevalence and intensity, and change in devel-
opment (i.e. cognitive, language and fine motor skills) between the 12 and 24-month visit. The
development outcomes are reported separately.
Prior to commencing recruitment, in-depth practical training of the research assistants took
place according to WHO guidelines [28,29] to ensure accurate outcome assessment and stan-
dardization. Inter and intra-rater reliability of over 95% was achieved for weight and length
assessments, which are considered acceptable levels for anthropometric measurements [28,30].
Methods used for outcome measurements are described elsewhere [14]. Briefly, weight was
measured using a portable electronic scale, accurate to the nearest 0.01 kg (Seca 334, Seca Corp.,
Baltimore, MD, USA). Length (i.e. the recommended measurement of height in children less
than two years of age) was measured in duplicate as recumbent crown-heel length on a flat sur-
face using a stadiometer (Seca 210, Seca Corp., Baltimore, MD, USA), accurate to the nearest
millimetre. One stool specimen per child was collected to assess STH (e.g. Ascaris, Trichuris and
hookworm) infection prevalence and intensity. For ethical reasons, only specimens from chil-
dren receiving deworming treatment were immediately examined by trained laboratory technol-
ogists at the local research facility using the Kato-Katz method (single slide) for the presence and
intensity (i.e. eggs per gram of feces) of STH infection [31]. At each time point, specimens from
those children receiving placebo were stored at room temperature in 10% formalin and analyzed
by the direct method for the presence of STH infection upon trial completion (Table 1).
This approach ensured that children found to be infected were treated. This approach also
aimed to minimize effect dilution which would have occurred if treatment had been provided
to those found to be STH positive, but randomized to receive placebo. The Kato-Katz method
is the recommended technique for assessment of the prevalence and intensity of intestinal par-
asitic infection in fresh stool [31]. For a one-stool specimen, sensitivity and specificity are over
96% for Ascaris and over 91% for Trichuris [32]. There is lower sensitivity and specificity for
hookworm; however, hookworm infection is generally uncommon in very young children in
this study area [13]. Additional details on the collection of stool specimens, including the ethi-
cal rationale for using two methods of analysis and how blinding was maintained, are published
Table 1. Randomly allocated treatment and corresponding analysis (method and timing) of stool specimens by group and visit.
Group Visit Treatment Specimen analysis (method) Specimen analysis (timing)
1 12-month Mebendazole* Kato-Katz Immediate
18-month Placebo** Direct Stored, analyzed after 24-month visit
24-month Mebendazole Kato-Katz Immediate
2 12-month Placebo Direct Stored, analyzed after 24-month visit
18-month Mebendazole Kato-Katz Immediate
24-month Mebendazole Kato-Katz Immediate
3 12-month Mebendazole Kato-Katz Immediate
18-month Mebendazole Kato-Katz Immediate
24-month Mebendazole Kato-Katz Immediate
4 12-month Placebo Direct Stored, analyzed after 24-month visit
18-month Placebo Direct Stored, analyzed after 24-month visit
24-month Mebendazole Kato-Katz Immediate
*single-dose 500 mg mebendazole tablet, crushed and mixed with juice
**single-dose tablet, identical in size, colour and markings to the mebendazole tablet
doi:10.1371/journal.pntd.0004020.t001
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elsewhere [14]. Lower sensitivity to detect STH infection from storage and later analysis of
specimens by the direct method was also anticipated [14].
A socio-demographic and epidemiological questionnaire was administered at each visit. At
the follow-up visits, this included a question on whether deworming had been received
between study visits (i.e. outside of the trial).
Information on minor and severe adverse events was obtained through passive reporting at fol-
low-up visits or in between visits. Severe adverse events were based onWHO definitions and
included: 1) death; 2) life-threatening conditions; 3) in-patient hospitalization or prolongation of
an existing hospitalization; 4) persistent or significant disability/incapacity; 5) cancer; or 6) over-
dose (accidental or intentional) [5]. All reported illnesses that did not meet the definition of a seri-
ous adverse event were considered to be minor adverse events. All adverse events were reported to
ethics committees. Summary reports of adverse events were also provided to the DSMC.
Data collection activities during fieldwork were regularly supervised by the Project Director
(SAJ) and local Project Coordinator (LP). The consistency of egg count assessments was evalu-
ated among the laboratory technologists using standard quality control methods [31]. The lab-
oratory supervisor read 10% of the slides of the laboratory technologists without prior
knowledge of the result to ensure quality control.
Analyses
Weight-for-age z scores (WAZ) and length-for-age z scores (LAZ) were calculated using WHO
Anthro software (Version 3, 2011). WHO categories were used to classify STH intensity
according to species-specific counts of eggs per gram of feces (epg) [33]. Both arithmetic and
geometric mean epg were calculated.
The primary outcome of the trial was mean weight gain in kilograms (kg) between the base-
line 12-month visit and the 24-month follow-up visit (i.e. after 12 months). Mean weight gain
(kg) was compared between the four intervention groups using unadjusted one-way ANOVA
procedure. Secondary analyses which were specified a priori were conducted to examine differ-
ences between intervention groups in terms of change in derived weight indices (i.e. meanWAZ
change) and length and derived length indices (mean length gain and mean LAZ change). Multi-
variable linear regression was also conducted adjusting for age, sex, socioeconomic status (based
on an asset-based proxy index) [34,35] and continued breastfeeding at 12 months of age.
All analyses were first expressed using an intention-to-treat (ITT) approach such that par-
ticipants were analyzed according to their assigned intervention group. Multiple imputation,
using a Markov Chain Monte Carlo (MCMC) model with five imputations, was used for those
who did not attend the 24-month follow-up visit. Variables related to the outcome, and
hypothesized to be related to missing the follow-up visit(s) were used to impute missing weight
and length measurements. These variables were baseline weight, length, socioeconomic status,
continued breastfeeding at 12 months, sex, and age. Imputation was done separately by ran-
domly assigned treatment group. Additional analyses were specified a posteriori, including: 1)
using a complete case approach on all participants who had attended the final follow-up visit,
2) using a per-protocol approach excluding those participants who did not attend all three vis-
its and/or who reported having received deworming outside of the trial between baseline and
the final follow-up visit and 3) restricted to children positive for STH infection at baseline.
These analyses were conducted for the following reasons: 1) complete case analyses were con-
ducted for comparison purposes with intention-to-treat analyses with imputed data; 2) per-
protocol analyses were conducted to account for higher than anticipated non-compliance to
the assigned intervention; and 3) subgroup analysis in STH-infected children were conducted
to account for the lower than anticipated baseline STH infection prevalence.
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The primary research question on the effect of deworming was determined by comparing
growth outcomes between each intervention group and the control group. To explore the sec-
ondary research question on the effect of the timing of deworming (i.e. at the 12-month visit or
at the 18-month visit), growth outcomes in Group 1 were compared to Group 2. To explore the
secondary research question on the effect of the frequency of deworming (i.e. provided once or
twice), growth outcomes in Group 1 and Group 2 were each compared to Group 3. All three
research questions were specified a priori.
The effect of deworming on STH indicators at 24 months was also examined using a gener-
alized linear model with a log link, a Poisson distribution, and a robust variance estimator to
estimate the risk ratio for the dichotomous outcomes of any STH infection, Ascaris infection,
Trichuris infection and hookworm infection, where no infection (i.e. no STH infection, no
Ascaris infection, no Trichuris infection and no hookworm infection, respectively) comprised
the reference group.
All statistical analyses were performed using the Statistical Analysis Systems statistical soft-
ware package version 9.3 (SAS Institute, Cary, NC, USA).
Results
Participant flow
Between September 2011 and June 2012, the parents of 2297 children were approached to par-
ticipate in the trial. Five-hundred and thirty-seven children were excluded as they did not meet
the inclusion criteria (n = 385), declined to participate (n = 126), or were approached but not
enrolled once the sample size was reached (n = 26). A total of 1760 children were randomized
to the four groups (Fig 1). All children received the assigned intervention at baseline. A total of
1606 children (91.2%) attended their first follow-up at the 18-month visit between March 2012
and January 2013. Due to parental refusal, three children did not receive their randomly allo-
cated intervention. The average time between the baseline and first follow-up visit was 6.3
months (± 0.41) and between the first follow-up visit and the second follow-up visit was 6.3
months (± 0.47). The average time between the baseline and second follow-up visit was 12.6
months (± 0.67). Time between visits was equivalent among intervention groups. The second
follow-up visit was completed between September 2012 and July 2013.
Compliance
A total of 1517 children (86.2%) attended all three visits. Of those who did not attend all three
visits, 108 (6.1%) attended the first visit only, 89 children (5.1%) attended the first and second
visits and 46 children (2.6%) attended the first and last visits. The proportion of children
reported to have received deworming outside of the trial during the study period was 25.7% in
Group 1; 26.8% in Group 2; 26.3% in Group 3; and 30.3% in Group 4. These differences were
not statistically significant (p = 0.49).
Characteristics of the study population
Baseline characteristics of the study population by intervention group are found in Table 2.
Groups were similar in terms of baseline weight (kg) and length (cm), age (months), birth
weight (kg) and length (cm), continued breastfeeding, up-to-date vaccinations and hospitaliza-
tions since birth. There were small differences in the proportion of girls in each group and vita-
min A supplementation in the previous year. In terms of maternal and household
characteristics, groups were similar in the proportion of mothers who were married or com-
mon-law, the level of maternal education, and access to potable water in the home. Small
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differences were found in maternal employment outside of the home and area of residence.
Baseline characteristics were similar between children who attended the final follow-up visit
and those who missed their final visit (S1 Table).
At baseline, the prevalence of any STH infection was 14.5% in the two groups whose speci-
mens were analyzed by the Kato-Katz method (i.e. 13.6% in MBD/PBO and 15.2% in MBD/
MBD) (Table 3). At the 18-month visit, any STH prevalence was 28.5% (i.e. 30.7% in PBO/
MBD and 26.4% in MBD/MBD). As expected due to lower sensitivity, STH prevalence in chil-
dren whose stool specimens were analyzed by the direct method at 12 and 18 months was mod-
erately lower (i.e. 10.5% and 24.5%, respectively). Certain sensitivity analyses were therefore
conducted in subgroups of children found to be STH-positive 1) by both the direct and Kato-
Katz methods and 2) only by the Kato-Katz method. Despite potential misclassification of STH
infection status in children whose specimens were analyzed by the direct method, this strategy
allowed for maximum comparison among all groups. Infection was predominantly low inten-
sity for Trichuris and hookworm infection at all three time points; however, moderate and
heavy intensity Ascaris infection increased over the one-year follow-up period (Table 3).
At the 24-month visit, at which time all specimens were analyzed by the Kato-Katz method,
the overall prevalence of any STH increased to 42.6%. Prevalence of Ascaris, Trichuris and any
STH infection was moderately lower in the groups which received deworming at the 18-month
visit. Hookworm infection remained negligible. No statistically significant difference in any STH
prevalence or Ascaris or hookworm prevalence was observed in any of the deworming interven-
tion groups compared to the control group; however, a statistically significantly lower prevalence
of Trichuris infection was observed in Group 3, which received mebendazole at both the 12 and
18-month visits, compared to the control group (RR = 0.69; 95% CI: 0.52, 0.90) (S2 Table).
Fig 1. Trial profile. *26 participants were screened but were not enrolled once the sample size was met. **1 Group 1 (MBD/PBO) = mebendazole (12
months)/placebo (18 months); 2 Group 2 (PBO/MBD) = placebo (12 months)/mebendazole (18 months); 3 Group 3 (MBD/MBD) = mebendazole (12 months)/
mebendazole (18 months); 4 Group 4 (PBO/PBO) = placebo (12 months)/placebo (18 months).
doi:10.1371/journal.pntd.0004020.g001
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Overall effect of deworming on primary and secondary anthropometric
outcomes
All groups gained between 1.93 and 2.05 kg in weight and between 9.61 and 9.84 cm in length,
on average over 12 months. The greatest changes in all growth outcomes between the 12- and
24-month visits were seen in Group 1 (Table 4). The average difference in weight gain (kg)
compared to placebo was: 0.05 (95% CI: -0.05, 0.17) in Group 1; -0.07 (95%CI: -0.17, 0.04) in
Group 2; and 0.04 (95%CI: -0.06, 0.14) in Group 3. When comparing the outcomes in each of
the deworming intervention groups to the control group, however, no statistically significant
effect was detected in unadjusted or adjusted ITT analysis (Table 4). No statistically significant
difference in any intervention group compared to the control group was seen in per-protocol
analysis (S3 Table), complete case analysis (S4 Table) or in analysis restricted to only those chil-
dren who were positive for STH infection at baseline (S5 Table).
Table 2. Baseline characteristics of the study population (N = 1760) by intervention group, Iquitos, Loreto, Peru (September 2011-July 2013).
MBD/PBO*1 PBO/MBD *2 MBD/MBD *3 PBO/PBO*4
(n = 440) (n = 440) (n = 440) (n = 440)
Child characteristics
Weight [mean kg (SD**)] 8.6 (1.0) 8.8 (1.0) 8.7 (1.0) 8.7 (0.9)
Length [mean cm (SD)] 71.9 (2.4) 72.3 (2.4) 72.1 (2.5) 72.2 (2.5)
Age [mean months (SD)] 12.5 (0.4) 12.5 (0.5) 12.5 (0.4) 12.5 (0.5)
Birth weight [mean kg (SD)] 3.1 (0.5) 3.2 (0.5) 3.2 (0.5) 3.2 (0.5)
Birth length [mean cm (SD)] 49.2 (2.5) 49.5 (2.5) 49.4 (2.3) 49.5 (2.7)
Sex [n (%) female] 215 (48.9) 222 (50.5) 203 (46.1) 200 (45.5)
Continued breastfeeding at 12 months [n (%)] 394 (89.6) 395 (89.8) 394 (89.6) 392 (89.1)
Up-to-date vaccinations*** [n (%)] 346 (78.8) 351 (79.8) 358 (81.6) 355 (80.9)
Received vitamin A in previous year [n (%)] 213 (48.4) 241 (54.8) 251 (57.1) 216 (49.1)
Hospitalizations since birth [n (%)] 402 (91.4) 397 (90.2) 402 (91.4) 396 (90.0)
Walking without support [n (%)] 111 (25.2) 104 (23.7) 117 (26.6) 101 (23.1)
Maternal characteristics
Married or common-law [n (%)] 358 (81.4) 351 (79.8) 357 (81.1) 357 (81.1)
Secondary education completed [n (%)] 142 (32.4) 140 (31.8) 133 (30.2) 139 (31.6)
Employment outside the home [n (%)] 47 (10.7) 45 (10.2) 50 (11.4) 37 (8.4)
Household characteristics
Peri-urban or rural residence [n (%)] 382 (86.8) 391 (88.9) 388 (88.2) 399 (90.7)
Potable water in home [n (%)] 230 (52.3) 218 (49.6) 230 (52.3) 220 (50.0)
Earth or wood house material [n (%)] 342 (77.7) 342 (77.7) 338 (76.8) 332 (75.5)
*1Group 1 (MBD/PBO) = mebendazole at the 12-month visit and placebo at the 18-month visit
2Group 2 (PBO/MBD) = placebo at the 12-month visit and mebendazole at the 18-month visit
3Group 3 (MBD/MBD) = mebendazole at the 12 and 18-month visit
4Group 4 (PBO/PBO) = placebo at the 12 and 18-month visit
**SD = standard deviation
***Up-to-date vaccinations include those scheduled between birth and 11 months of age (i.e. one dose of Bacille Calmette-Guérin (BCG), one dose of
hepatitis B, three doses of polio, three doses of pentavalent, two doses of rotavirus, and two doses of pneumococcal)
doi:10.1371/journal.pntd.0004020.t002
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Table 3. Soil-transmitted helminth (STH) infection prevalence and intensity at the a) 12-month (n = 880)*1, b) 18-month (n = 807)*2 and c) 24-month
(n = 1563)*3 follow-up visits by intervention group, Iquitos, Loreto, Peru (September 2011-July 2013).
a) 12-month visit b) 18-month visit
MBD/PBOǂ1 (n = 440) MBD/MBDǂ3 (n = 440) PBO/MBDǂ2 (n = 401) MBD/MBDǂ3 (n = 405)
Ascaris lumbricoides
Prevalence (#, %) 48 (10.9) 52 (11.8) 93 (23.2) 82 (20.2)
Intensity
No (#, %) 392 (89.1) 388 (88.2) 308 (76.8) 323 (79.8)
Light (#, %) 40 (9.1) 46 (10.4) 73 (18.2) 56 (13.8)
Moderate (#, %) 8 (1.8) 6 (1.4) 17 (4.2) 25 (6.2)
Heavy (#, %) 0 (0.0) 0 (0.0) 3 (0.8) 1 (0.2)
AM† (95% CI) 321.2 (171.4, 471.1) 253.9 (144.6, 363.2) 1524.6 (668.2, 2381.1) 1227.7 (687.9, 1767.5)
GM§ (95% CI) 2.2 (1.8, 2.8) 2.2 (1.8, 2.8) 5.4 (3.9, 7.3) 4.5 (3.3, 6.1)
Trichuris trichiura
Prevalence (#, %) 17 (3.9) 22 (5.0) 55 (13.7) 44 (10.8)
Intensity
No (#, %) 423 (96.2) 418 (95.0) 346 (86.3) 361 (89.2)
Light (#, %) 16 (3.6) 20 (4.6) 52 (13.0) 41 (10.1)
Moderate (#, %) 1 (0.2) 2 (0.4) 3 (0.7) 3 (0.7)
AM (95% CI) 18.0 (-4.4, 40.5) 15.1 (3.8, 26.4) 41.5 (9.7, 73.2) 30.8 (10.6, 51.0)
GM (95% CI) 1.2 (1.1, 1.3) 1.3 (1.2, 1.4) 1.9 (1.6, 2.2) 1.7 (1.5, 2.0)
Hookworm
Prevalence (#, %) 3 (0.7) 2 (0.5) 1 (0.3) 6 (1.5)
Intensity
No (#, %) 437 (99.3) 438 (99.5) 400 (99.8) 399 (98.5)
Light (#, %) 3 (0.7) 2 (0.5) 1 (0.2) 6 (1.5)
AM (95% CI) 1.4 (-0.9, 3.7) 0.7 (-0.5, 1.8) 1.5 (-1.4, 4.4) 3.6 (-0.7, 7.9)
GM (95% CI) 1.03 (1.0, 1.1) 1.0 (1.0, 1.0) 1.0 (1.0, 1.0) 1.1 (1.0, 1.1)
ANY STH INFECTION
Prevalence (#, %) 60 (13.6) 67 (15.2) 123 (30.7) 107 (26.4)
c) 24-month visit MBD/PBOǂ1 (n = 388) PBO/MBDǂ2 (n = 398) MBD/MBDǂ3 (n = 381) PBO/PBOǂ4 (n = 396)
Ascaris lumbricoides
Prevalence (#, %) 128 (33.0) 127 (31.9) 117 (30.7) 128 (32.3)
Intensity
No (#, %) 260 (67.0) 271 (68.1) 264 (69.3) 268 (67.7)
Light (#, %) 85 (21.9) 88 (22.1) 82 (21.5) 88 (22.2)
Moderate (#, %) 40 (10.3) 37 (9.3) 33 (8.7) 38 (9.6)
Heavy (#, %) 3 (0.8) 2 (0.5) 2 (0.5) 2 (0.5)
AM (95% CI) 2246.7 (1491.9, 3001.4) 2442.5 (948.3, 3936.7) 2205.5 (1179.9, 3231.2) 1952.0 (1238.8, 2665.2)
GM (95% CI) 12.1 (8.3, 17.4) 10.7 (7.5, 15.2) 9.5 (6.7, 13.5) 10.3 (7.3, 14.6)
Trichuris trichiura
Prevalence (#, %) 100 (25.8) 83 (20.9) 68 (17.9) 103 (26.0)
Intensity
No (#, %) 288 (74.2) 315 (79.1) 313 (82.2) 293 (74.0)
Light (#, %) 97 (25.0) 82 (20.6) 66 (17.3) 100 (25.3)
Moderate (#, %) 3 (0.8) 1 (0.3) 2 (0.5) 3 (0.7)
AM (95% CI) 57.5 (31.0, 84.0) 26.4 (16.8, 35.9) 34.1 (16.5, 51.8) 55.6 (36.8, 74.3)
GM (95% CI) 3.3 (2.7, 4.1) 2.5 (2.1, 2.9) 2.2 (1.9, 2.7) 3.4 (2.8, 4.2)
HOOKWORM
(Continued)
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Effect of deworming timing on primary and secondary anthropometric
outcomes
In examining the effect of the timing at which deworming was administered, a statistically sig-
nificant improvement was seen in Group 1 compared to Group 2, in terms of weight gain
(unadjusted difference 0.12 kg; 95% CI: 0.01; 0.23), length gain (unadjusted difference 0.31 cm;
95% CI: 0.04, 0.58), WAZ change (unadjusted difference 0.13; 95% CI: 0.03, 0.23), and LAZ
change (unadjusted difference: 0.12; 95% CI: 0.03, 0.21) between baseline and the final follow-
up visit in unadjusted analyses (S6 Table). These results remained significant in adjusted analy-
ses (S6 Table) per-protocol analysis (S7 Table), complete case analysis (S8 Table). In subgroup
analyses restricted to children positive for STH infection at baseline, no significant differences
were observed between groups (S9 Table).
Effect of deworming frequency on primary and secondary
anthropometric outcomes
In comparing the difference in anthropometric outcomes between Group 1, receiving deworm-
ing once yearly, and Group 3, receiving deworming twice yearly, no additional benefit on
weight or length was apparent for twice-yearly deworming in unadjusted or adjusted analyses
(S10 Table). Results remained consistent in per-protocol analysis (S11 Table), complete case
analysis (S12 Table) and in restricted analyses to children infected with STH at baseline (S13
Table). A statistically significant benefit, however, was observed in Group 3 compared to
Group 2, in terms of weight gain andWAZ change. These results remained significant for both
weight gain and WAZ change when adjusting for baseline characteristics, in per-protocol and
complete case analyses.
Table 3. (Continued)
a) 12-month visit b) 18-month visit
MBD/PBOǂ1 (n = 440) MBD/MBDǂ3 (n = 440) PBO/MBDǂ2 (n = 401) MBD/MBDǂ3 (n = 405)
Prevalence (#, %) 4 (1.0) 6 (1.5) 5 (1.3) 9 (2.3)
Intensity
No (#, %) 384 (99.0) 392 (98.5) 376 (98.7) 387 (97.7)
Light (#, %) 4 (1.0) 6 (1.5) 5 (1.3) 9 (2.3)
AM (95% CI) 1.4 (-0.6, 3.4) 1.6 (-0.2, 3.3) 2.1 (-0.4, 4.7) 7.5 (-2.2, 17.2)
GM (95% CI) 1.0 (1.0, 1.1) 1.1 (1.0, 1.1) 1.1 (1.0, 1.1) 1.1 (1.0, 1.2)
ANY STH INFECTION
Prevalence (#, %) 175 (45.1) 163 (41.0) 149 (39.1) 179 (45.2)
* STH results at all visits include only children whose specimens were analyzed by the Kato-Katz method (i.e. 1Group 1 and Group 3 at 12-month visit;
2Groups 2 and 3 at 18-month visit (results were not available for 73 children who were lost to follow-up); 3All groups at the 24-month visit (results were not
available for 197 children who were lost to follow-up))
ǂ1Group 1 (MBD/PBO) = mebendazole at the 12-month visit and placebo at the 18-month visit
2Group 2 (PBO/MBD) = placebo at the 12-month visit and mebendazole at the 18-month visit
3Group 3 (MBD/MBD) = mebendazole at the 12 and 18-month visit
4Group 4 (PBO/PBO) = placebo at the 12 and 18-month visit
†AM = arithmetic mean eggs per gram
§GM = geometric mean eggs per gram. A value of 1 was added to each observation to calculate the geometric mean.
The prevalence of stunting and underweight increased from 24.2% and 8.6% at baseline to 46.8% and 10.2%, respectively, at the 24-month visit.
doi:10.1371/journal.pntd.0004020.t003
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Table 4. Overall primary effect of deworming on anthropometric outcomes over 12months, using one-way ANOVA andmultivariable linear regres-
sion analyses (N = 1760*), Iquitos, Loreto, Peru (September 2011 – July 2013).
MBD/PBO**1 PBO/MBD**2 MBD/MBD**3 PBO/PBO**4
(n = 440) (n = 440) (n = 440) (n = 440)
Primary outcome
Weight gain, kg 2.05 1.93 2.04 2.00
(95% CI) (1.98, 2.13) (1.85, 2.02) (1.97, 2.11) (1.93, 2.06)
Unadjusted difference 0.05 -0.07 0.04 reference
(95% CI) (-0.05, 0.16) (-0.17, 0.04) (-0.06, 0.14)
p-value 0.322 0.217 0.442
Adjustedǂ difference 0.06 -0.06 0.05 reference
(95% CI) (-0.05, 0.17) (-0.16, 0.04) (-0.05, 0.15)
p-value 0.289 0.259 0.318
Secondary outcomes
Length gain, cm 9.84 9.53 9.67 9.61
(95% CI) (9.64, 10.05) (9.33, 9.74) (9.50, 9.85) (9.41, 9.81)
Unadjusted difference 0.23 -0.08 0.06 reference
(95% CI) (-0.07, 0.53) (-0.38, 0.23) (-0.21, 0.34)
p-value 0.129 0.626 0.651
Adjusted difference 0.26 -0.06 0.12 reference
(95% CI) (-0.04, 0.55) (-0.36, 0.25) (-0.15, 0.39)
p-value 0.087 0.714 0.390
WAZ†1 change -0.23 -0.36 -0.24 -0.28
(95% CI) (-0.30, -0.16) (-0.43, -0.29) (-0.30, -0.18) (-0.34, -0.22)
Unadjusted difference 0.05 -0.08 0.04 reference
(95% CI) (-0.05, 0.14) (-0.17, 0.01) (-0.05, 0.13)
p-value 0.321 0.090 0.359
Adjusted difference 0.05 -0.07 0.04 reference
(95% CI) (-0.04, 0.15) (-0.16, 0.02) (-0.05, 0.13)
p-value 0.277 0.126 0.339
LAZ†2 change -0.51 -0.64 -0.56 -0.59
(95% CI) (-0.58, -0.44) (-0.71, -0.57) (-0.62, -0.49) (-0.66, -0.52)
Unadjusted difference 0.07 -0.05 0.03 reference
(95% CI) (-0.02, 0.17) (-0.15, 0.05) (-0.06, 0.13)
p-value 0.132 0.328 0.474
Adjusted difference 0.09 -0.04 0.04 reference
(95% CI) (-0.01, 0.18) (-0.14, 0.06) (-0.05, 0.13)
p-value 0.083 0.454 0.377
Results are expressed as mean (95% Conﬁdence Interval)
* Intention-to-treat analysis includes data from 1563 children for whom ﬁnal outcome information was available, and 197 children who were lost to follow-
up and whose outcome information was estimated using multiple imputation
**1Group 1 (MBD/PBO) = mebendazole at the 12-month visit and placebo at the 18-month visit
2Group 2 (PBO/MBD) = placebo at the 12-month visit and mebendazole at the 18-month visit
3Group 3 (MBD/MBD) = mebendazole at the 12 and 18-month visit
4Group 4 (PBO/PBO) = placebo at the 12 and 18-month visit
ǂ Adjusted models include age, sex, socioeconomic status and continued breastfeeding at 12 months of age
†
1WAZ = weight-for-age z score
2LAZ = length-for-age z score. Z scores were derived using WHO international growth standards [36]
doi:10.1371/journal.pntd.0004020.t004
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Adverse events
From baseline until the end of follow-up, 38 minor adverse events were reported and were sim-
ilarly distributed among groups (i.e. Group 1: 7; Group 2: 10; Group 3: 12; and Group 4: 9).
There were 18 serious adverse events reported: Group 1: 5 deaths and 2 hospitalizations;
Group 2: 1 death and 0 hospitalizations; Group 3: 3 deaths and 2 hospitalizations; and Group
4: 2 deaths and 3 hospitalizations. Ten serious adverse events occurred after administration of
mebendazole (i.e. 7 deaths and 3 hospitalizations) and eight serious adverse events occurred
after administration of placebo (i.e. 4 deaths and 4 hospitalizations). The range of time between
administration of the randomized intervention and occurrence of the serious adverse event
was 6 days to 6 months for hospitalizations and 18 days and 7 months for deaths. None of
these serious adverse events were deemed to be related to the deworming intervention by the
DSMC, Research Ethics Committees in Canada and Peru, or the trial investigators.
Discussion
This is the largest double-blind, randomized, placebo-controlled trial of deworming to our
knowledge that has been conducted exclusively in children during the second year of life. This
is the age at which WHO first recommends starting mass deworming programs, and it is also a
time of rapid growth, development and STH acquisition. Our trial had several strengths. These
include: 1) its randomized controlled design, which minimized confounding and the influence
of external factors; 2) a large sample size, so that primary analyses were sufficiently powered; 3)
a high follow-up rate, despite a highly mobile population and environmental challenges such
as flooding which displaced many participants in the study area; 4) consistency of results in
intention-to-treat, complete case and per-protocol analyses, demonstrating that results from
children attending the final study visit are likely generalizable to the original trial population;
and 5) community-based canvassing in the study area prior to recruitment to attempt to reach
the entire study population [14].
Overall effect of deworming
We were not able to demonstrate an overall benefit on the primary research question of
deworming on growth between any of the intervention groups compared to the control group
after one year of follow-up in intention-to-treat analysis or in further sensitivity analyses. Our
results are consistent with a recent cluster-randomized trial of albendazole (administered every
six months to children from six months to six years of age) conducted in north India where
light intensity STH infection was also predominant [21]. It is also consistent with a study in
Uganda in children aged 15 months to 5 years who received quarterly albendazole [22]. Our
findings do, however, contradict other trials in preschool-age children that found a positive
effect of deworming on growth indicators [12,20].
The lack of benefit in our study compared to these other studies could reflect a true lack of
effect of deworming on growth in the time period and/or study population. This population of
children has a high level of malnutrition that may not be able to be treated solely by one or two
doses of deworming in a one-year time period. In addition, we were not able to demonstrate a
statistically significant reduction in any STH or species-specific prevalence with any of the
deworming interventions, except for a reduction in Trichuris infection with twice-yearly
deworming. The poor effect of the deworming intervention on STH prevalence measured after
6 and 12 months was almost certainly influenced by the dynamics of re-infection and new
infection occurring between study time points. Future studies, which are adequately powered
to detect changes in STH infection over time, are needed to confirm these findings.
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If there were, however, a true effect that was not observed, the short follow-up time may
have limited the potential to detect this benefit. It is likely that, in the one year period of our
study, a steady state has not yet been achieved, in terms of either STH infection (e.g. as evi-
denced by the over threefold increase in STH prevalence from 12 to 24 months of age) or
growth (e.g. as evidenced by a negative deviation of WAZ and LAZ compared to the interna-
tional WHO growth standard over 12 months). Benefits of the deworming intervention may be
apparent only with a longer follow-up time.
The low prevalence and intensity of infection, in particular, may have limited the impact of
deworming, which reduces morbidity primarily through a reduction in moderate and heavy
intensity infection. In deworming interventions, nutritional improvements are not a direct
consequence of drug administration but a result of the elimination of parasites that are compet-
ing for nutrients. When the intervention is administered to a population with low prevalence
and/or intensity, the short-term benefits could be difficult to measure. WHO recommends the
periodic (once or twice-yearly) administration of antihelminthics as a means of controlling
morbidity from STH infection. The nutritional benefits are a consequence of the maintenance
of very a low level of these infections in childhood.
The baseline prevalence of STH infection in the study population was lower than had been
anticipated based on a study conducted in the area just three to four years prior (i.e. in 2007
and 2008) [13]. The number of children who could have potentially benefited from deworming
in the trial was therefore reduced, resulting in a reduction in power to detect an effect of the
expected size. Results from a previous trial suggested that deworming could improve growth in
young children, even with low intensity infection [12]; however, we did not observe this in our
trial. Preventive chemotherapy programs include treatment of both infected and uninfected
children; nonetheless, our results suggest that research studies should be conducted in areas of
high STH prevalence to ensure as little effect dilution as possible. With increasing implementa-
tion of deworming programs, a rapid assessment in the age group and study area to determine
baseline prevalence and intensity may be warranted before beginning any research study.
Effect of deworming timing and frequency
Our trial was unique in using a multiple group design to look additionally at the secondary
research questions of differences in the timing and frequency among the groups that received
deworming. Such considerations are important in operationalizing deworming interventions
in this age group. Our results suggest that, if deworming is provided between one and two
years of age, there is a significant benefit of providing it earlier rather than later. Our results
also demonstrate that there was no added benefit from an additional dose provided at 18
months of age (over and above that at 12 months of age). These results were consistent in
unadjusted and adjusted analysis, as well as in sensitivity analyses, for multiple growth indica-
tors. A true benefit of earlier deworming compared to later deworming is biologically plausible,
as suggested in nutritional research showing the importance of incorporating interventions as
early as possible to prevent adverse health and nutritional consequences [16]. However, in light
of the lack of benefit of any of the deworming interventions compared to the control group and
the low STH prevalence and intensity at baseline, these results should be interpreted with cau-
tion. The difference in growth between Groups 1 and 2 may be due to a shorter follow-up from
the time of intervention to the time of outcome measurement (i.e. 12 months in Group 1 vs. 6
months in Group 2), or a chance finding of lower average weight gain in Group 2 compared to
all three other groups. Although the number of statistically significant findings was more than
due to chance alone, and all comparisons, except for sensitivity analyses (i.e. complete case,
per-protocol, and subgroup analyses in STH-infected individuals), were specified a priori, we
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cannot rule out the possibility that this difference could be a spurious finding due to chance
alone.
Compliance
One issue that arose after beginning the study was difficulty with compliance, as over 25% of
children received deworming at least once outside of the assigned intervention group. A higher
proportion of children in the control group had been reported to have received deworming
outside of the trial, but this proportion was not statistically significantly different from the
other groups. Even after taking non-compliance into account by conducting a per-protocol
analysis, excluding those who took deworming outside of the trial and/or who did not attend
all three study visits, no statistically significant difference in growth outcomes was observed.
The ease of access to deworming was an unexpected result as deworming is not routinely pro-
vided to children under two years of age in the study area; however, this level of access to
deworming outside of the study protocol has been observed in other trials in preschool-age
children [22]. With the growing presence of deworming campaigns and availability of antihel-
minthics without a prescription in many countries, this finding of non-compliance will likely
become increasingly common. Although for ethical and logistical purposes we could not
restrict access to antihelminthics outside of the trial, it is imperative that compliance is mea-
sured in all deworming research studies and taken into account in the analysis of results.
Stool specimen analysis
For ethical and scientific reasons, we did not immediately analyze stool specimens from chil-
dren randomized to placebo at the 12 or 18-month visits. This meant that accurate STH preva-
lence and intensity were not available for those receiving placebo (i.e. Group 2 (PBO/PBO) and
Group 3 (MBD/MBD) at 12 months, and Group 1 (MBD/PBO) and Group 3 (MBD/MBD) at
18 months), and that results from the Kato-Katz and direct methods were not easily compara-
ble (Table 1). Examining a single stool specimen with a single technique (i.e. Kato-Katz) may
have also decreased the sensitivity to detect STH infection, particularly in those with low inten-
sity infection [37]; however, considering the sample size and age group of children in the study,
the collection of multiple specimens was not considered to be feasible. Our strategy had the
advantage of providing accurate overall baseline STH prevalence of the study population (as all
groups would be expected to have similar baseline prevalences due to randomization), and
accurate final STH prevalences at the 24-month visit (at which time all groups were analyzed
by the Kato-Katz method). As STH infection status was a secondary outcome (weight gain
being the primary outcome), misclassification of infection status would not have affected the
analyses on growth or on the effect of the deworming intervention on STH infection at the
24-month visit. Misclassification might have affected only the secondary subgroup analyses
restricted to the STH-infected population. Despite the limitations to the strategy we employed,
we consider ours to have methodological advantages to other strategies which have been used,
such as: 1) not collecting stool specimens, which provides no information on baseline or fol-
low-up STH infection[20], or; 2) analyzing all stool specimens immediately, and treating those
found to be infected, regardless of allocated intervention group, which would dilute the effect
size by providing treatment to those randomized to placebo if found to be STH-positive [22].
Future research focus and directions
Overall, this is the first trial to provide evidence on the effect of deworming, including optimal
timing and frequency, on growth exclusively in children in the critical time window between
one and two years of age. This trial demonstrated the feasibility of incorporating deworming
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into routine growth and development health clinics along with other essential early childhood
interventions. We were also able to demonstrate safety of the deworming intervention in this
age group, with similar numbers of serious adverse events occurring after mebendazole and
placebo administration. This is consistent with results from previous studies [22,23,38]. Con-
tinued observational follow-up of the trial cohort is currently taking place, and will provide evi-
dence on the longer-term effects of deworming up to five years of age.
Future studies looking at the benefit of deworming on growth in this age group should include
study areas of higher STH prevalence and/or intensity, higher potential compliance to the assigned
intervention (i.e. lower availability of anthelminthics in the community) and longer follow-up
time. Further studies should include other factors that are important to consider for scaling up
deworming interventions in this age group. This includes: 1) cost-effectiveness of preventive che-
motherapy vs. analyzing and treating only infected individuals; 2) feasibility and cost-effectiveness
of integrating deworming with other health, nutritional and environmental interventions, particu-
larly health education and micronutrient supplementation; 3) health and nutritional consequences
of low intensity infection in younger age groups; and 4) inclusion of high-risk children living in
more remote areas and/or those who do not regularly attend health services. This type of research
is essential to contribute to strengthening the evidence base on deworming.
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